12.50
+5.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Abcellera Biologics
From its filings with the US Securities and Exchange Commission
Abcellera Biologics is based in Vancouver, British Columbia, Canada and is incorporated in British Columbia, Canada. Its shares trade on Nasdaq under the ticker ABCL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $75.1m and a net loss of $146.4m. At that date it held total assets of $1.36bn and shareholders' equity of $966.9m. By region, Canada accounted for 85.2%, followed by United States at 14.8%.
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates. While we historically used our platform for our partners’ programs, we have evolved our strategy to build our own internal pipeline of AbCellera-owned drug assets.
As of December 31, 2025, we have approximately $700 million in available liquidity to continue executing on our strategy. We believe we have the capital to fund our operations beyond the next three years. We expect to generate losses and negative operating cash flow in the near-to-medium term ahead of revenues generated from out-licensing programs and milestone payments and royalties in the longer term.
Our strategy is to use our competitive advantage to create innovative and impactful medicines for patients. Our strategy is indication-agnostic. We evaluate and seek to advance programs where we have confidence in the science; can pursue a significant commercial opportunity resulting from addressing an unmet medical need; possess potential for differentiation; and see a clear development path with early opportunity to retire risk.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 11 Dec 2020
- Employees
- 562
- Website
- abcellera.com ↗
- Head office
- 150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6
- Incorporated in
- A1
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Carl HansenChairman of the Board, President, Chief Executive Officer, Co-Founder, since 2012$8.2m
- Dr. Veronique LecaultCo-Founder, Chief Operating Officer, Director, since 2018$3.4m
- Mr. Andrew BoothChief Financial Officer, since 2016$3.4m
- Mr. Tryn StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer, since 2023$2.9m
- Dr. Sarah NoonbergChief Medical Officer
- Dr. Michael HaydenLead Independent Director$416,284
- Dr. Andrew LoIndependent Director$374,459
- Mr. John MontalbanoIndependent Director$388,784
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 44
- Social
- 59
- Governance
- 25
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Abcellera Biologics Inc. possesses several strengths that contribute to its success:
Weaknesses
- Despite its strengths, Abcellera Biologics Inc. also experiences certain weaknesses:
Opportunities
- Abcellera Biologics Inc. has various opportunities for growth and expansion:
Threats
- The following threats pose challenges for Abcellera Biologics Inc.:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.